In contrast, ABCG2 (BCRP) was found to mediate the efflux of sorafenib; where co-treatment of sorafenib with an ABCG2 inhibitor greatly augmented the cytotoxicity in HCC cells [43]. Here, ABCG2 is linked to hepatocellular carcinoma.